Skip to content
Primary Mediastinal B-cell Lymphoma (PMBCL) episode artwork

Jan 25, 2026 16 min

Primary Mediastinal B-cell Lymphoma (PMBCL)

from OrphaChat — a Rare Disease Podcast Hosted by RCH

These sources examine the biological characteristics and evolving management of primary mediastinal B-cell lymphoma (PMBCL) and related aggressive malignancies. The texts highlight the Janus kinase/signal transducers (JAK-STAT) and NF-κB pathways as central drivers of the disease, which distinguish it from other lymphoma subtypes. Current frontline strategies focus on dose-adjusted EPOCH-R and R-CHOP regimens, often utilizing PET-CT scans to determine the necessity of consolidative radiotherapy. For patients with relapsed or refractory disease, emerging research evaluates the high efficacy of CAR T-cell therapy and immune checkpoint inhibitors like pembrolizumab. Furthermore, the literature introduces bispecific monoclonal antibodies, such as glofitamab and epcoritamab, as breakthrough options that redirect T-cells to target malignant cells. Ultimately, the collection emphasizes the shift towards precision medicine and targeted immunotherapies to improve outcomes for patients who fail traditional treatments.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Primary Mediastinal B-cell Lymphoma (PMBCL)

0:00 16:50

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OrphaChat — a Rare Disease Podcast?

This episode is 16 minutes long.

When was this OrphaChat — a Rare Disease Podcast episode published?

This episode was published on January 25, 2026.

Can I download this OrphaChat — a Rare Disease Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.